What smart money is saying about Heartflow, Inc.
3 funds in our archive have pitched Heartflow, Inc. — most recently Baron Discovery Fund in March 2026.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Get an email when a fund writes about it
Position history
Between Q3 2025 and Q2 2026, 2 fund letters reported a position in Heartflow, Inc. — 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 2 | 0 | 2 | 0 |
| Q1 2026 | 0 | 0 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Fund activity · 2 positions · 2 moves
- ExitedBaron SMID Cap ETFJune 2026
“Top net sales for the quarter Year Acquired Market Cap When Acquired ($B) Market Cap When Sold ($B) Net Amount Sold ($K) Booz Allen Hamilton Holding Corporation 2025 11.3 8.5 652.6 Insulet Corporation 2025 20.8 11.1 594.7 Heartflow, Inc. 2026 1.9 2.5 382.8 Rambus Inc. 2026 10.7 12.0 363.3 Monolithic Power Systems, Inc. 2025 45.6 67.9 327.5 Booz Allen Hamilton Holding Corporation is a provider of IT services for state and federal governmental entities. The company has stabilized its revenue base after experiencing meaningful declines in its federal civil segment caused by cost reduction initiatives in the federal government. While we admire the company and its management, we are increasingly concerned that IT consulting is becoming more commoditized, and we believe we can find more protected areas within IT for our capital. Insulet Corporation is the global leader in tubeless automated insulin delivery (AID) devices. It has over 600,000 active global customers using its AID devices and had $2.7 billion in revenues in 2025 which is a fraction of the $19 billion worldwide type 1 diabetes market it predicts in 2028, and the additional $12 billion type 2 market in 2028. We sold our position in the quarter to re-evaluate the accelerating competitive landscape and to assess a series of safety issues that have affected Insulet’s AID production. We admire the company and its products and are keeping Insulet on our radar. Heartflow, Inc. is a provider of software that analyzes CT scans (with contrast) of a patient’s coronary arteries, and shows calcification, plaque buildup, and blood flow quality in a three-dimensional model. We sold the position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.”
Heartflow, Inc. - TrimmedBaron SMID Cap StrategyJune 2026
“Heartflow, Inc. is a provider of software that analyzes CT scans (with contrast) of a patient’s coronary arteries and shows calcification, plaque buildup, and blood flow quality in a three- dimensional model. We sold the position in the quarter as we grew incrementally more concerned about the presence of competitors on the market.”
Heartflow, Inc.
Fund coverage · 3 theses
- Baron Discovery FundMarch 2026
Heartflow develops FDA-approved AI software for non-invasive coronary analysis with strong customer trust and resilience to AI disintermediation.
Read the full thesis - Baron Opportunity FundDecember 2025
Heartflow, Inc. is an AI-powered cardiac diagnostics company with a deep data moat, regulatory approvals, and early penetration supporting scalable, high-margin growth.
Read the full thesis - Baron Global Opportunity FundSeptember 2025
Heartflow, Inc. is a promising medical device company leveraging AI to accurately diagnose heart disease, addressing a critical need in healthcare with significant growth potential and a strong competitive advantage.
Read the full thesis
Read every full thesis on Heartflow, Inc.
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→